{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:26:04Z","timestamp":1784751964193,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"We thank Pfizer for their provision of palbociclib and their financial contribution to this clinical study."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-024-00710-x","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:35:05Z","timestamp":1732610105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-5080","authenticated-orcid":false,"given":"Sonia","family":"Pernas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Perell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorea","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyukta","family":"Chillara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"710_CR1","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 23, 382\u2013392 (2022)."},{"key":"710_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1101\/gad.7.5.812","volume":"7","author":"V Baldin","year":"1993","unstructured":"Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. & Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812\u2013821 (1993).","journal-title":"Genes Dev."},{"key":"710_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/0092-8674(95)90034-9","volume":"82","author":"P Sicinski","year":"1995","unstructured":"Sicinski, P. et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82, 621\u2013630 (1995).","journal-title":"Cell"},{"key":"710_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn, R. S. et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25\u201335 (2015).","journal-title":"Lancet Oncol."},{"key":"710_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382, 514\u2013524 (2020).","journal-title":"N. Engl. J. Med."},{"key":"710_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100629","volume":"7","author":"V Di Lauro","year":"2022","unstructured":"Di Lauro, V. et al. Health-related quality of life in breast cancer patients treated with CDK4\/6 inhibitors: a systematic review. ESMO Open 7, 100629 (2022).","journal-title":"ESMO Open"},{"key":"710_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","volume":"32","author":"M Martin","year":"2021","unstructured":"Martin, M. et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann. Oncol. J. Eur. Soc. Med. Oncol. 32, 488\u2013499 (2021).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"710_CR8","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver, J. A. et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer Res J. Am. Assoc. Cancer Res 21, 4760\u20134766 (2015).","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"key":"710_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","volume":"183","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res. Treat. 183, 419\u2013428 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"710_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"710_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","volume":"40","author":"M Gnant","year":"2022","unstructured":"Gnant, M. et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03). J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 40, 282\u2013293 (2022).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"710_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the penelope-B trial. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 39, 1518\u20131530 (2021).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"710_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston, S. R. D. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 24, 77\u201390 (2023).","journal-title":"Lancet Oncol."},{"issue":"Jun","key":"710_CR14","doi-asserted-by":"publisher","first-page":"LBA500","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","volume":"41","author":"DJ Slamon","year":"2023","unstructured":"Slamon, D. J. et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: Primary results from the phase III NATALEE trial. J. Clin. Oncol. 41(Jun), LBA500\u2013LBA500 (2023).","journal-title":"J. Clin. Oncol."},{"key":"710_CR15","doi-asserted-by":"crossref","unstructured":"Dooper M. monarchE: No predictive biomarkers revealed with molecular profiling. In: Giles R., editor. Medicom Conference Report SABCS 2023 [Internet]. San Antonio, TX, USA: Medicom Medical Publishers; 2024 [cited 2024 Feb 27]. Available from: https:\/\/conferences.medicom-publishers.com\/?p=37272.","DOI":"10.55788\/4b33d2f6"},{"key":"710_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston, S. et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 37, 178\u2013189 (2019).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"710_CR17","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","volume":"29","author":"P Cottu","year":"2018","unstructured":"Cottu, P. et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann. Oncol. J. Eur. Soc. Med. Oncol. 29, 2334\u20132340 (2018).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"710_CR18","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"710_CR19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/annonc\/mdy202","volume":"29","author":"M Arnedos","year":"2018","unstructured":"Arnedos, M. et al. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Ann. Oncol. J. Eur. Soc. Med Oncol. 29, 1755\u20131762 (2018).","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"key":"710_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-017-4329-y","volume":"165","author":"R Goncalves","year":"2017","unstructured":"Goncalves, R. et al. Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res. Treat. 165, 355\u2013364 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"710_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 (2020).","journal-title":"Lancet Oncol."},{"key":"710_CR22","doi-asserted-by":"publisher","first-page":"16889","DOI":"10.1002\/cam4.6315","volume":"12","author":"D Hequet","year":"2023","unstructured":"Hequet, D. et al. Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings. Cancer Med. 12, 16889\u201316895 (2023).","journal-title":"Cancer Med."},{"key":"710_CR23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.21037\/tcr-22-2807","volume":"12","author":"S Zhao","year":"2023","unstructured":"Zhao, S., Zhang, H., Yang, N. & Yang, J. A narrative review about CDK4\/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer. Transl. Cancer Res. 12, 1617\u20131634 (2023).","journal-title":"Transl. Cancer Res."},{"key":"710_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/diagnostics13050987","volume":"13","author":"IM Stanciu","year":"2023","unstructured":"Stanciu, I. M. et al. Mechanisms of resistance to CDK4\/6 inhibitors and predictive biomarkers of response in HR+\/HER2-metastatic breast cancer\u2014a review of the literature. Diagnosis 13, 987 (2023).","journal-title":"Diagnosis"},{"key":"710_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamaoncol.2023.2000","volume":"9","author":"CC O\u2019Sullivan","year":"2023","unstructured":"O\u2019Sullivan, C. C., Clarke, R., Goetz, M. P. & Robertson, J. Cyclin-dependent kinase 4\/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncol. 9, 1273\u20131282 (2023).","journal-title":"JAMA Oncol."},{"key":"710_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 23, 149\u2013160 (2022).","journal-title":"Lancet Oncol."},{"key":"710_CR27","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.3390\/cancers13215477","volume":"13","author":"AJA Freitas","year":"2021","unstructured":"Freitas, A. J. A. et al. Molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: review. Cancers 13, 5477 (2021).","journal-title":"Cancers"},{"key":"710_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104148","volume":"192","author":"G Antonarelli","year":"2023","unstructured":"Antonarelli, G. et al. The CDK4\/6 inhibitors biomarker landscape: the most relevant biomarkers of response or resistance for further research and potential clinical utility. Crit. Rev. Oncol. Hematol. 192, 104148 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"710_CR29","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","volume":"34","author":"LN Harris","year":"2016","unstructured":"Harris, L. N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 34, 1134\u20131150 (2016).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"710_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-016-3725-z","volume":"156","author":"M Martin","year":"2016","unstructured":"Martin, M. et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM\/9906 sub-study. Breast Cancer Res. Treat. 156, 81\u201389 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"710_CR31","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.21037\/gs-21-566","volume":"10","author":"Z Cao","year":"2021","unstructured":"Cao, Z. et al. Prognostic and tumor-immune infiltration cell signatures in tamoxifen-resistant breast cancers. Gland Surg. 10, 2766\u20132779 (2021).","journal-title":"Gland Surg."},{"key":"710_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","volume":"20","author":"G Petroni","year":"2020","unstructured":"Petroni, G., Formenti, S. C., Chen-Kiang, S. & Galluzzi, L. Immunomodulation by anticancer cell cycle inhibitors. Nat. Rev. Immunol. 20, 669\u2013679 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"710_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00625-7","volume":"10","author":"T Pascual","year":"2024","unstructured":"Pascual, T. et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ Breast Cancer 10, 20 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"710_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. J. Eur. Soc. Med. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"710_CR35","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"710_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","volume":"18","author":"A Llombart-Cussac","year":"2017","unstructured":"Llombart-Cussac, A. et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 18, 545\u2013554 (2017).","journal-title":"Lancet Oncol."},{"key":"710_CR37","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamaoncol.2016.0922","volume":"2","author":"A Prat","year":"2016","unstructured":"Prat, A. et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. JAMA Oncol. 2, 1287\u20131294 (2016).","journal-title":"JAMA Oncol."},{"key":"710_CR38","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","volume":"16","author":"TO Nielsen","year":"2010","unstructured":"Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 16, 5222\u20135232 (2010).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-024-00710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-024-00710-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-024-00710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:02:48Z","timestamp":1732611768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-024-00710-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1038\/s41523-024-00710-x","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P.: consulting or advisory role for Novartis, Pfizer, SeaGen, AstraZeneca, Daiichi Sankyo, and Pierre Fabre. Speakers\u2019 Bureau for: Novartis, Lilly, Roche, Gilead Sciences, Pfizer, Daiichi Sankyo\/AstraZeneca and research funding (to institute) from Roche, outside of the submitted work. ESF: The authors declare no potential conflicts of interest. G.V.: speaker\u2019s fee from MSD, Pfizer, GSK and Pierre Fabre, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics. J.S.: Advisory role: Lilly, Novartis, AstraZeneca, Gilead. Speakers\u2019 Bureau for: Novartis, Roche, Pfizer and Daiichi Sankyo. Travel and accommodation for Roche and Novartis. A.P.: The authors declare no potential conflicts of interest. X.G.: Astra Zeneca (travel), Novartis (speaker), Pierre Fabre (speaker). B.J.: Invited speaker (Novartis, Lilly, Roche, Daiichi Sankyo), Advisory Board (Esteve), travel fees for congresses (Daiichi Sankyo). M.M.: The authors declare no potential conflicts of interest. PP: travel support from MSD, Lilly, Pharmamar, GSK; speakers AstraZeneca, GSK, Clovis, Pfizer. T.P.: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers\u2019 bureaus) from Astra Zeneca, Novartis, Pfizer, Veracyte and Lilly; Consulting Fees (e.g., advisory boards) from Novartis. E.A.: Advisory role: Novartis, Pfizer, Lilly, Gilead, AstraZeneca, Exact Science. Investigation grant: Pfizer. L.V.: The authors declare no potential conflicts of interest. S.C.: The authors declare no potential conflicts of interest. JMFC: The authors declare no potential conflicts of interest. PG: The authors declare no potential conflicts of interest. A.P.: Personal financial interests: Lecture fees (AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo), Advisory role\/consultancy (Roche, Pfizer, Novartis, Guardant Health, Peptomyc & Lilly), Leadership role (Reveal Genomics, SL; Pangea, 1TrialSP sc). Institutional financial interests: Contracted research (AstraZeneca, Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia Innovation Research SL, Pfizer). Leadership roles: Executive boards (Pangaea, 1TrialSP, SL), Patronage committee (Actitud Frente al C\u00e1ncer Foundation), co-founder and CSO (Reveal Genomics, SL). E.C.: Personal financial interest: Advisory Board (AstraZeneca, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer, Roche, Gilead, Seagen), Invited Speaker (Lilly, Pfizer, Roche, Seagen), Speakers Bureau (Roche), Travel accommodation (AstraZeneca). No financial interest: principal investigator for TATEN trial (sponsor SOLTI group), Patricia 2 trial (sponsor: SOLTI Group), Prometeo 2 trial (sponsor: SOLTI Group), ATREZZO trial (sponsor: SOLTI Group), Scientific Evaluator at Instituto de Salud Carlos III, advisory role (Spanish Government Academic Research Platform) and SOLTI Cooperative Group, Member of Board of Directors, Non-profit organization dedicated to breast cancer research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}